Literature DB >> 28729334

CD70 turns on NK cells to attack lymphoma.

Todd A Fehniger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28729334      PMCID： PMC5520476          DOI： 10.1182/blood-2017-06-786244

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.

Authors:  Maximillian Rosario; Bai Liu; Lin Kong; Lynne I Collins; Stephanie E Schneider; Xiaoyue Chen; Kaiping Han; Emily K Jeng; Peter R Rhode; Jeffrey W Leong; Timothy Schappe; Brea A Jewell; Catherine R Keppel; Keval Shah; Brian Hess; Rizwan Romee; David R Piwnica-Worms; Amanda F Cashen; Nancy L Bartlett; Hing C Wong; Todd A Fehniger
Journal:  Clin Cancer Res       Date:  2015-09-30       Impact factor: 12.531

Review 2.  NK cell recognition.

Authors:  Lewis L Lanier
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 3.  CD27 and CD70 in T cell and B cell activation.

Authors:  Jannie Borst; Jenny Hendriks; Yanling Xiao
Journal:  Curr Opin Immunol       Date:  2005-06       Impact factor: 7.486

4.  B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.

Authors:  Andrea Borgerding; Justin Hasenkamp; Michael Engelke; Nina Burkhart; Lorenz Trümper; Jürgen Wienands; Bertram Glass
Journal:  Exp Hematol       Date:  2010-01-06       Impact factor: 3.084

5.  CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.

Authors:  Mohamad F Al Sayed; Carla A Ruckstuhl; Tamara Hilmenyuk; Christina Claus; Jean-Pierre Bourquin; Beat C Bornhauser; Ramin Radpour; Carsten Riether; Adrian F Ochsenbein
Journal:  Blood       Date:  2017-05-11       Impact factor: 22.113

6.  CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Roch Houot; Matthew J Goldstein; Kipp Weiskopf; Ash A Alizadeh; Josh Brody; Antonia Müller; Russell Pachynski; Debra Czerwinski; Steven Coutre; Mark P Chao; Lieping Chen; Thomas F Tedder; Ronald Levy
Journal:  Blood       Date:  2010-12-30       Impact factor: 22.113

7.  Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Ariane Thielens; Aurelien Marabelle; Idit Sagiv-Barfi; Caroline Sola; Fabien Chanuc; Nicolas Fuseri; Cécile Bonnafous; Debra Czerwinski; Amanda Rajapaksa; Erin Waller; Sophie Ugolini; Eric Vivier; François Romagné; Ronald Levy; Mathieu Bléry; Pascale André
Journal:  Blood       Date:  2013-12-10       Impact factor: 22.113

Review 8.  Human natural killer cells.

Authors:  Michael A Caligiuri
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

Review 9.  NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.

Authors:  Wei Wang; Amy K Erbe; Jacquelyn A Hank; Zachary S Morris; Paul M Sondel
Journal:  Front Immunol       Date:  2015-07-27       Impact factor: 7.561
  9 in total
  1 in total

Review 1.  Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.

Authors:  Yuchen Wang; Hao Zhang; Chao Liu; Zeyu Wang; Wantao Wu; Nan Zhang; Longbo Zhang; Jason Hu; Peng Luo; Jian Zhang; Zaoqu Liu; Yun Peng; Zhixiong Liu; Lanhua Tang; Quan Cheng
Journal:  J Hematol Oncol       Date:  2022-08-17       Impact factor: 23.168
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.